Michael, R. Loken

Michael, R. Loken's AcademicInfluence.com Rankings

Michael, R. Loken

Biology

#9348

World Rank

#12543

Historical Rank

Immunology

#556

World Rank

#575

Historical Rank

biology Degrees

Download Badge

Biology

Michael, R. Loken's Degrees

PhD Immunology Stanford University

Why Is Michael, R. Loken Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Michael, R. Loken's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule. (1983) (1273)
The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. (1986) (1096)
Characterization of the Murine Antigenic Determinant, Designated L3T4a, Recognized by Monoclonal Antibody GK 1.5: Expression of L3T4a by Functional T Cell Clones Appears to Correlate Primarily with Class II MHC Antigen‐Reactivity (1983) (1028)
Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+CD38- progenitor cells. (1991) (933)
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. (2001) (861)
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. (2007) (477)
Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development. (1987) (477)
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence (2005) (422)
ANALYSIS OF CELL POPULATIONS WITH A FLUORESCENCE‐ACTIVATED CELL SORTER * (1975) (397)
Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. (2003) (326)
Establishing optimal lymphocyte gates for immunophenotyping by flow cytometry. (1990) (265)
A role for tumour necrosis factor‐α, Fas and Fas‐Ligand in marrow failure associated with myelodysplastic syndrome (1998) (253)
Flow cytometry as an analytical and preparative tool in immunology. (1982) (245)
Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. (2012) (238)
Cloned T Lymphocytes and Monoclonal Antibodies as Probes for Cell Surface Molecules Active in T Cell‐Mediated Cytolysis (1982) (236)
Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. (2005) (236)
Antigenic analysis of hematopoiesis. VI. Flow cytometric characterization of My-10-positive progenitor cells in normal human bone marrow. (1987) (232)
Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin) (2002) (220)
Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group (2012) (215)
Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes (2009) (205)
Flow cytometric analysis of human bone marrow: I. Normal erythroid development (1987) (202)
Flow cytometric analysis of human bone marrow: I. Normal erythroid development. (1987) (199)
CD45 Gating for Routine Flow Cytometric Analysis of Human Bone Marrow Specimens (1993) (198)
Flow cytometric analysis of human bone marrow. III. Neutrophil maturation. (1990) (197)
Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. (2002) (182)
Two-color immunofluorescence using a fluorescence-activated cell sorter. (1977) (180)
CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. (2007) (176)
Human lymphocyte subpopulations identified by using three-color immunofluorescence and flow cytometry analysis: correlation of Leu-2, Leu-3, Leu-7, Leu-8, and Leu-11 cell surface antigen expression. (1984) (161)
Identification and characterization of plasma cells in normal human bone marrow by high-resolution flow cytometry (1990) (151)
Flow cytometric analysis of human bone marrow. IV. Differential quantitative expression of T-200 common leukocyte antigen during normal hemopoiesis. (1988) (150)
Murine T Lymphocyte Clones with Distinct Immunological Functions (1981) (143)
Myeloid cell differentiation in normal bone marrow and acute myeloid leukemia assessed by multi-dimensional flow cytometry. (1990) (143)
Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions (2017) (141)
Negative Regulators of Hemopoiesis and Stroma Function in Patients with Myelodysplastic Syndrome (2000) (131)
I-A antigens on cloned alloreactive murine T lymphocytes are acquired passively. (1982) (130)
Asynchronous Antigen Expression in B Lineage Acute Lymphoblastic Leukemia (1988) (128)
Identification and characterization of plasma cells in normal human bone marrow by high-resolution flow cytometry. (1990) (127)
Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis. (2001) (120)
Cell surface antigens on human marrow cells: dissection of hematopoietic development using monoclonal antibodies and multiparameter flow cytometry. (1987) (116)
S-phase detection with an antibody to bromodeoxyuridine. Role of DNase pretreatment. (1986) (111)
Cell discrimination by multiangle light scattering. (1976) (109)
Quantitative Comparison of Myeloid Antigens on Five Lineages of Mature Peripheral Blood Cells (1990) (107)
Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome. (2008) (107)
Allotypic specificities of murine IgD and IgM recognized by monoclonal antibodies. (1984) (105)
Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome. (2005) (103)
CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531. (2016) (101)
CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531. (2017) (100)
Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. (2008) (98)
Discriminating between damaged and intact cells in fixed flow cytometric samples. (1988) (97)
Expression of IgD by murine lymphocytes. Loss of surface IgD indicates maturation of memory B cells (1978) (97)
Flow cytometry in myelodysplastic syndromes: report from a working conference. (2008) (95)
Flow cytometric characterization of acute myeloid leukemia. Part II. Phenotypic heterogeneity at diagnosis. (1992) (93)
Evidence of donor-derived hematologic malignancies after hematopoietic stem cell transplantation. (2006) (93)
Simultaneous quantitation of Hoechst 33342 and immunofluorescence on viable cells using a fluorescence activated cell sorter. (1980) (91)
Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry. (1996) (89)
NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report. (2014) (86)
Multiparameter flow cytometric analysis of human fetal bone marrow B cells. (1990) (81)
Five-dimensional flow cytometry as a new approach for blood and bone marrow differentials. (1988) (81)
Positive stem cell selection--basic science. (1990) (80)
Simultaneous analysis of cell surface antigens, bromodeoxyuridine incorporation and DNA content. (1985) (76)
Normalization of bone marrow aspirates for hemodilution in flow cytometric analyses (2009) (76)
Lyt-2-/Lyt 3- variants of a cloned cytolytic T cell line lack an antigen receptor functional in cytolysis (1981) (71)
Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children’s Oncology Group (2020) (68)
Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group (2012) (67)
Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group (2017) (66)
Multidimensional flow cytometry of marrow can differentiate leukemic from normal lymphoblasts and myeloblasts after chemotherapy and bone marrow transplantation. (1998) (65)
Isolation of CD34+ cells from blood stem cell components using the Baxter Isolex system (1998) (65)
A rapid sample preparation technique for flow cytometric analysis of immunofluorescence allowing absolute enumeration of cell subpopulations. (1989) (64)
Structural differences in cell surface T25 polypeptides from thymocytes and cloned T cells. (1981) (61)
Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes. (2011) (60)
A clone-specific monoclonal antibody that inhibits cytolysis of a cytolytic T cell clone (1983) (59)
Increased light scattering resolution facilitates multidimensional flow cytometric analysis. (1990) (59)
Onset of DNA synthesis during the cell cycle in chemostat cultures. (1967) (58)
High molecular weight lymphocyte surface proteins are structurally related and are expressed on different cell populations at different times during lymphocyte maturation and differentiation. (1982) (58)
Three-color immunofluorescence analysis of Leu antigens on human peripheral blood using two lasers on a fluorescence-activated cell sorter. (1984) (57)
NOD/SCID mice transplanted with marrow from patients with myelodysplastic syndrome (MDS) show long-term propagation of normal but not clonal human precursors. (2003) (57)
Flow cytometric analysis of normal B lymphoid development. (1988) (55)
Asynchronous antigen expression in B lineage acute lymphoblastic leukemia. (1988) (54)
Evidence that juvenile myelomonocytic leukemia can arise from a pluripotential stem cell. (2000) (52)
Interaction between I region loci influences the expression of a cell surface Ia antigen. (1980) (52)
CTLA-4 blockade by a human MAb enhances the capacity of AML-derived DC to induce T-cell responses against AML cells in an autologous culture system. (2006) (52)
Clinical Significance of CD33 Nonsynonymous Single-Nucleotide Polymorphisms in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab-Ozogamicin–Containing Chemotherapy (2013) (50)
Separation of viable T and B lymphocytes using a cytochemical stain, Hoechst 33342. (1980) (50)
Flow cytometric characterization of acute myeloid leukemia. Part 1. Significance of light scattering properties. (1991) (48)
Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group (2015) (47)
Intensive postgrafting immune suppression combined with nonmyeloablative conditioning for transplantation of HLA-identical hematopoietic cell grafts: results of a pilot study for treatment of primary immunodeficiency disorders (2007) (41)
Identification of cell asymmetry and orientation by light scattering. (1977) (40)
Inhibition of proliferation of MIs- and Ia-reactive cloned T cells by a monoclonal antibody against a determinant shared by I-A and I-E. (1983) (39)
Flow Cytometry Principles for Clinical Laboratory Practice: Quality Assurance for Quantitative Immunophenotyping (1994) (39)
Multidimensional flow cytometric blood cell differentiation without erythrocyte lysis. (1991) (38)
High expression of the very late antigen-4 integrin independently predicts reduced risk of relapse and improved outcome in pediatric acute myeloid leukemia: a report from the children's oncology group. (2010) (37)
Discordant expression of AC133 and AC141 in patients with myelodysplastic syndrome (MDS) and acute myelogeneous leukemia (AML) (2000) (37)
Surface markers and functional relationships of cells involved in murine B-lymphocyte differentiation. (1977) (37)
Assessment of proliferation during maturation of the B lymphoid lineage in normal human bone marrow. (1988) (36)
A recurrent immunophenotype at diagnosis independently identifies high-risk pediatric acute myeloid leukemia: a report from Children’s Oncology Group (2016) (34)
Somatic mutations in the HLA genes of patients with hematological malignancy. (2012) (33)
DNL 1.9: a monoclonal antibody which specifically detects all murine B lineage cells (1981) (32)
AAML0523: A report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia (2014) (32)
Assessment of normal erythropoiesis by flow cytometry: important considerations for specimen preparation (2014) (31)
Tumor-specific aneuploidy not detected in CD19+ B-lymphoid cells from myeloma patients in a multidimensional flow cytometric analysis. (1996) (30)
Monoclonal antibodies to rabbit lymphoid cells: preparation and characterization of a T-cell-specific antibody. (1981) (30)
Detection of genomic abnormalities in multiple myeloma: the application of FISH analysis in combination with various plasma cell enrichment techniques. (2011) (30)
Occult B cell malignancies can be detected by three-color flow cytometry in patients with cytopenias (1998) (29)
Functional Properties of KIT Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia (2019) (29)
Flow Cytometry for Diagnosis and Assessment of Prognosis in Patients with Myelodysplastic Syndromes (2004) (29)
Clonal evolution of myeloma cells leads to quantitative changes in immunoglobulin secretion and surface antigen expression. (1979) (28)
Simultaneous analysis of DNA content and surface antigens in human bone marrow. (1988) (27)
Lack of utility of chimerism studies obtained 2–3 months after myeloablative hematopoietic cell transplantation for ALL (2008) (26)
CEBPA bZip Mutations are Associated with Favorable Prognosis in de novo AML: A Report from the Children's Oncology Group. (2021) (26)
Identification of lysis-relevant molecules on the surface of CTL: primary screening of monoclonal antibodies for the capacity to block cytolysis by cloned CTL lines. (1982) (26)
ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children’s Oncology Group AAML0531 Trial (2019) (25)
Comparison of helium-neon and dye lasers for the excitation of allophycocyanin. (1987) (25)
Assessment of erythroid dysplasia by “Difference from normal” in routine clinical flow cytometry workup (2014) (25)
Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression. (2018) (25)
Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-Positive AML Defines Novel Therapeutic Options — a COG and Target Pediatric AML Study (2018) (24)
Allotypes of mouse IgM immunoglobulin (1977) (24)
Two color light scattering identifies physical differences between lymphocyte subpopulations. (1982) (24)
The biologic significance of rare peripheral blasts after hematopoietic cell transplantation is predicted by multidimensional flow cytometry. (1999) (23)
miR‐155 expression and correlation with clinical outcome in pediatric AML: A report from Children's Oncology Group (2016) (22)
Detection of minimal residual disease in acute myelogenous leukemia. (1995) (22)
Phenotypic abnormalities strongly reflect genotype in patients with unexplained cytopenias (2011) (22)
Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children’s Oncology Group protocol AAML0531 (2017) (21)
FLT3 ligand promotes engraftment of allogeneic hematopoietic stem cells without significant graft-versus-host disease1 (2003) (21)
Nonrandom escape of tumor cells from immune lysis due to intraclonal fluctuations in antigen expression. (1983) (21)
Basal levels of CD34 positive cells in peripheral blood differ between individuals and are stable for 18 months (2012) (21)
Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report from the Children's Oncology Group Protocol AAML1031 (2019) (20)
Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531 (2021) (20)
Effects of isolation on interferon production and hematological and immunological parameters. (1992) (20)
Human "null" cells mediating antibody-dependent cellular cytotoxicity express T lymphocyte differentiation antigens. (1980) (20)
Light scattered at two wavelengths can discriminate viable lymphoid cell populations on a fluorescence-activated cell sorter. (1981) (20)
Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group (2013) (18)
Antigenic analysis of hematopoiesis. IV. The My-11 hematopoietic cell surface antigen is expressed by myelomonocytic and lymphoid, but not erythroid, progenitor cells. (1986) (18)
Coordinate glycosylation and cell surface expression of glycophorin A during normal human erythropoiesis. (1987) (18)
Revised Risk Stratification Criteria for Children with Newly Diagnosed Acute Myeloid Leukemia: A Report from the Children's Oncology Group (2017) (18)
Minimal residual disease detected prior to hematopoietic cell transplantation (2011) (18)
Constancy of cell buoyant density for cultured murine cells (1984) (18)
Haemopoietic reconstitution by donor‐derived myelodysplastic progenitor cells after haemopoietic stem cell transplantation (1999) (17)
Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse (2004) (16)
Alteration of clonal profile II. Studies on the capacity of BALB/c splenic B cells to perpetuate responsiveness to phosphorylcholine and T15 idiotypic dominance (1981) (16)
Direct determination of the influence of the cell cycle on the survival of tumor cells exposed to cytotoxic antibodies. (1980) (15)
Routine quantitation of white cells as low as 0.001 per microL in platelet components (1993) (15)
Deciphering the Significance of CD56 Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group (2020) (15)
Time-dependent resistance or susceptibility of tumor cells to cytotoxic antibody after exposure to a chemotherapeutic agent. (1978) (14)
Flow cytometric analysis of human bone marrow : I . Normal erythroid (2005) (14)
Graft-versus-leukemia effect in acute lymphoblastic leukemia: the importance of tumor burden and early detection (2004) (14)
Array-based karyotyping in plasma cell neoplasia after plasma cell enrichment increases detection of genomic aberrations. (2012) (13)
Residual disease in AML, a target that can move in more than one direction (2014) (13)
Consistent quantitative gene product expression: #1. Automated identification of regenerating bone marrow cell populations using support vector machines (2016) (13)
The Addition of Bortezomib to Standard Chemotherapy for Pediatric Acute Myeloid Leukemia Has Increased Toxicity without Therapeutic Benefit: A Report from the Children's Oncology Group (2016) (13)
Changes in susceptibility to cytotoxic antibody among tumor cells surviving exposure to chemotherapeutic agents. (1982) (13)
Quantitative fluorescence analysis of cyclosporine binding to human leukocytes. (1984) (12)
The role of flow cytometry in myelodysplastic syndromes. (2008) (12)
Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemia. (2021) (12)
Long-term engraftment and clonal dominance of donor-derived del(20q) hematopoietic cells after allogeneic stem cell transplantation. (2006) (11)
Flow cytometric mean fluorescence intensity: the biophysics behind the number. (2008) (11)
Flow cytometric analysis of myelodysplasia: Pre‐analytical and technical issues—Recommendations from the European LeukemiaNet (2021) (11)
Treatment of 11q23/MLL + AML with Gemtuzumab Ozogamicin: Results from the Randomized Phase III Children's Oncology Group Trial AAML0531 (2015) (11)
Multidimensional Data Analysis in Immunophenotyping (1997) (11)
CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group (2021) (11)
Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia (2021) (10)
Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031 (2022) (10)
Analysis of human lymphocyte protein expression I. Identification of subpopulation markers by two‐dimensional polyacrylamide gel electrophoresis (1988) (10)
Detection of clonal evolution in hematopoietic malignancies by combining comparative genomic hybridization and single nucleotide polymorphism arrays. (2014) (10)
Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS‐Flow Cytometry Working Group (2021) (10)
Evaluating optical filter efficiency in a flow cytometer. (1980) (10)
JAK2V617F mutation can occur exclusively in the erythroid lineage and be absent in granulocytes and progenitor cells in classic myeloproliferative disorders (2006) (10)
A clone specific monoclonal antibody which inhibits T cell-mediated cytolysis. (1982) (10)
Expression of sialosyl-T and disialosyl-T antigens in erythroid cells. (1997) (9)
Hemoglobin function in stored blood. IX. Preservative with pH to maintain red blood cell 2,3-DPG (function) and ATP (viability). (1972) (9)
CD 33 Expression and Its Association With Gemtuzumab Ozogamicin Response : Results From the Randomized Phase III Children ’ s Oncology Group Trial AAML 0531 (2018) (9)
CD33_PGx6_Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group. (2019) (9)
Immunoglobulin isoantigens (allotypes) in the mouse (2005) (9)
Prognostic significance of flow cytometric residual disease, dysregulated neutrophils/monocytes, and hematogones in adult acute myeloid leukemia in first remission (2014) (9)
High-dose AraC is Essential for the Treatment of ML-DS Independent of Post-Induction MRD: Results of COG AAML1531. (2021) (8)
Conventional Cytogenetics, Molecular Profiling, and Flow Cytometric Response Data Allow the Creation of a Two-Tiered Risk-Group System for Risk-Based Therapy Allocation In Childhood AML- a Report From the Children's Oncology Group (2010) (8)
Assessment of erythroid dysplasia by "difference from normal" in routine clinical flow cytometry work-up. (2014) (8)
Flow cytometric detection of nonneoplastic antigenic polymorphisms of donor origin after allogeneic marrow transplant (2004) (8)
Comprehensive Transcriptome Profiling of Cryptic CBFA2T3–GLIS2 Fusion–Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML Study (2019) (8)
CCGG deletion (rs201074739) in CD33 results in premature termination codon and complete loss of CD33 expression: another key variant with potential impact on response to CD33-directed agents (2019) (8)
Consistent quantitative gene product expression: #3. Invariance with age (2016) (8)
Detection of occult lymphoma cells in bone marrow aspirates by multi-dimensional flow cytometry. (1992) (8)
T15 idiotype expression in the murine response to phosphorylcholine is actively regulated by genes linked to the Igh-C locus. (1986) (8)
Consistent quantitative gene product expression: #2. Antigen intensities on bone marrow cells are invariant between individuals (2016) (8)
Residual disease in AML, a target that can move in more than one direction. (2013) (7)
Multidimensional Flow Cytometry Significantly Improves Upon the Morphologic Assessment of Post-Induction Marrow Remission Status – Comparison of Morphology and Multidimensional Flow Cytometry; A Report From the Children's Oncology Group AML Protocol AAML0531 (2011) (7)
Minimal disease detection and confirmation in hematologic malignancies: combining cell sorting with clonality profiling. (2006) (7)
TWO-COLOR IMMUNOFLUORESCENCE USING A FLUORESCENCE- (1977) (7)
Morphologic remission status is limited compared to ΔN flow cytometry: a Children's Oncology Group AAML0531 report. (2020) (7)
Flow cytometric detection of nonneoplastic antigenic polymorphisms of donor origin after allogeneic marrow transplant: a report of two cases. (2004) (7)
Characterization of Erythroid, Lymphoid and Monomyeloid Lineages in Normal Human Bone Marrow (1992) (7)
Indoximod Combined with Standard Induction Chemotherapy Is Well Tolerated and Induces a High Rate of Complete Remission with MRD-Negativity in Patients with Newly Diagnosed AML: Results from a Phase 1 Trial (2018) (6)
Clone-specific MYD88 L265P and CXCR4 mutation status can provide clinical utility in suspected Waldenström macroglobulinemia/lymphoplasmacytic lymphoma. (2016) (6)
CD33 splicing SNP regulates expression levels of CD33 in normal regenerating monocytes in AML patients (2018) (6)
Evidence for BCR/ABL1‐positive T‐cell acute lymphoblastic leukemia arising in an early lymphoid progenitor cell (2019) (6)
Acute Myeloid Leukemia with RAM Immunophenotype: A Pediatric Case with Unusual Morphologic Features (2017) (6)
Discovery and Validation of Cell-Surface Protein Mesothelin (MSLN) As a Novel Therapeutic Target in AML: Results from the COG/NCI Target AML Initiative (2016) (6)
Characterization of murine hemopoietic cells using rat anti-mouse monoclonal antibodies. (1983) (6)
Distribution of orally administered bromine-82 in tubercular meningitis: concise communication. (1977) (5)
Correlation of CD123 Expression Level with Disease Characteristics and Outcomes in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group (2019) (5)
The skin test antigen stimulated killer (STAK) cell mediating NK like CMC is OKM1 positive and OKT3 negative. (1983) (5)
Minimal Residual Disease Detection by Four-Color Multidimensional Flow Cytometry Identifies Pediatric AML Patients at High Risk of Relapse. (2007) (5)
Sub-Morphologic Evidence of Disease Prior to Stem Cell Transplantation Correlates with Inferior Post Transplant Outcome in Childhood Acute Myeloid Leukemia. (2009) (5)
Rapid separation of whole human bone marrow aspirates by counterflow centrifugation elutriation. (1987) (5)
Transcriptome Profiling of Glycosylation Genes Defines Correlation with E-Selectin Ligand Expression and Clinical Outcome in AML (2019) (5)
Multidimensional Flow Cytometry for Detection of Rare Populations in Hematological Malignancies (2009) (5)
Characterization of functionally distinct subpopulations of rabbit T lymphocytes. (1984) (5)
Heritable and non-heritable variations in the phenotype of myeloma cells as detected by a fluorescence-activated cell sorter. (1979) (4)
Cytarabine dose reduction in patients with low‐risk acute myeloid leukemia: A report from the Children's Oncology Group (2021) (4)
Promyelocytic Leukemia with No Retinoic Acid Receptor Alpha Abnormality but with RUNX1T1 Insertion to Chromosome 7q: A Classification and Management Dilemma (2015) (4)
A minority of concurrent monoclonal lymphocytes and plasmacytic cells sharing light chains are genetically related in putative lymphoplasmacytic lymphoma. (2011) (4)
CONTROL OF CLONED ALLOREACTIVE T LYMPHOCYTE PROLIFERATIVE RESPONSES: A POSSIBLE ROLE FOR CELL‐SURFACE-BOUND ALLOANTIGEN (1984) (4)
Prospective Study on the Clinical Relevance of Residual Disease in Patients with Acute Myeloid Leukemia in Complete Remission (1994) (4)
Novel CD33 antibodies unravel localization, biology and therapeutic implications of CD33 isoforms. (2020) (4)
Children's Mercy Kansas City (2020) (4)
Outcomes of intensification of induction chemotherapy for children with high‐risk acute myeloid leukemia: A report from the Children's Oncology Group (2021) (3)
Impact Of Residual Disease On Survival In Pediatric Patients Receiving Allogeneic Hematopoietic Cell Transplantation For Acute Myeloid Leukemia In First Complete Remission (2013) (3)
High-Dose Cytarabine Is Indispensable for the Survival of Children with Myeloid Leukemia of Down Syndrome Despite Negative Minimal Residual Disease Post-Induction (2019) (3)
Negative Prognostic Impact Of High CD33 Expression Is Negated With The Use Of Gemtuzumab Ozogamicin: A Report From The Children’s Oncology Group (2013) (3)
Intraclonal heterogeneity in concomitant monoclonal lymphocyte and plasma cell populations: combining flow cytometric cell sorting with molecular monoclonality profiling. (2013) (3)
Blood Count Recovery Following Induction Therapy for Acute Myeloid Leukemia in Children Does Not Predict Survival (2022) (3)
Heirarchical Clustering of Immunophenotypic Cell Surface Antigen Expression Identifies Clinically Meaningful Cohorts in Childhood AML: A Report from the Children's Oncology Group Protocol AAML0531 (2015) (3)
CD117 Expression Is Associated with Cytogenetic and Molecular Profiles and Outcome in Pediatric Acute Myeloid Leukemia (2019) (2)
CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target (2022) (2)
A Comparative Assessment of Flow Cytometric Scoring Systems in MDS (2014) (2)
Effect of intensification of induction II chemotherapy and liberalization of stem cell donor source on outcome for children with high risk acute myeloid leukemia: A report from the Children’s Oncology Group. (2019) (2)
CBFA2T3-GLIS2 induces Malignant Transformation of Primitive CD34+ Cord Blood Cells and Recapitulates Infant Megakaryocytic Leukemia (2019) (2)
Therapeutic targeting of PRAME with mTCRCAR T cells in acute myeloid leukemia (2022) (2)
A B-cell developmental gene regulatory network is activated in infant AML (2021) (2)
Mobilization of Ph chromosome‐negative peripheral blood stem cells in a child with chronic myeloid leukemia after imatinib‐induced complete molecular remission (2008) (2)
Monitoring AML Response Using “Difference from Normal” Flow Cytometry (2018) (2)
Down Syndrome AML Is Unique in Phenotype Both at Diagnosis and in Post Chemotherapy Regeneration (2016) (2)
Newly Diagnosed Childhood AML Patients Treated with Bortezomib Show Superior Survival If CD74 Is Expressed: A Report of 991 Patients from the Children's Oncology Group AAML1031 Protocol (2020) (2)
Expression of a 16,000 molecular weight antigen on human suppressor T lymphocytes. (1981) (1)
Two B-cell subpopulations identified by flow cytometry. (1985) (1)
Therapeutic Targeting of CD74 with STRO-001 Antibody-Drug Conjugate in AML and ALL (2021) (1)
Presence of Residual Disease Detected by Multidimensional Flow Cytometry Identifies Patients with AML At High Risk of Relapse – a Report From the Children's Oncology Group, (2011) (1)
Association of CD33 Expression Level with Disease Risk-Group Classification and Induction Response In Pediatric AML: A Report From the Children's Oncology Group (2010) (1)
MYD88 L265P Mutation Detection: Analysis of Flow Cytometry Sorted Plasma and Lymphoid Cell Clones Improves Sensitivity and Specificity for WM/LPL Diagnosis (2014) (1)
Response to “Severe pernicious anemia with distinct cytogenetic and flow cytometric aberrations mimicking myelodysplastic syndrome” (2012) (1)
Enhancement of Eligibility Guidelines for Gemtuzumab Ozogamicin Therapy for Childhood Acute Myeloid Leukemia: A Report from Children's Oncology Group Protocol AAML0531 (2018) (1)
Identification of Post-Induction Minimal Residual Disease by Multidimensional Flow Cytometry Identifies Patients with AML at High Risk of Relapse and Poor Outcome- a Report From the Children's Oncology Group (2010) (1)
Array-Based Karyotyping Post Plasma Cell Enrichment for the Detection of Genomic Abnormalities in Multiple Myeloma (2012) (1)
Hemoglobin Function in Stored Blood. IX. A Modified Preservative with Optimal pH to Maintain Red Cell 2,3-DPG (Function) and ATP (Viability). (1971) (1)
Integrated analysis of genotype and phenotype reveals clonal evolution and cytogenetically driven disruption of myeloid cell maturation in myelodysplastic syndromes (2021) (1)
Phase II results of mitoxantrone in combination with clofarabine in children with relapsed/refractory acute leukemia. (2019) (1)
SNP/CGH Microarray Analysis in MDS: Correlation with Conventional Cytogenetic, FISH and Flow Cytometry Findings (2014) (1)
Relationship between CD33 Expression, P-Glycoprotein-Mediated Drug Efflux, and Clinical Outcome in Patients Treated in Phase II Trials with Gemtuzumab Ozogamicin Monotherapy. (2006) (1)
No Adverse Effect of Residual Neoplastic Mast Cells in Systemic Mastocytosis Associated with Acute Myeloid Leukemia with T ( 8 ; 21 ) ( Q 22 ; Q 22 ) ; Runx 1-Runx 1 t 1 after Bone Marrow Transplantation (2014) (1)
Targeting FOLR1 in High-Risk CBF2AT3-GLIS2 AML with Stro-002 FOLR1-Directed Antibody-Drug Conjugate (2021) (1)
Therapeutic Targeting of Mesothelin in Acute Myeloid Leukemia with Chimeric Antigen Receptor T Cell Therapy (2020) (1)
Postgrafting Immune Suppression Combined with Nonmyeloablative Conditioning for Transplantation of HLA-Identical Hematopoietic Cell Grafts: Results of a Phase I Study for Treatment of Immunodeficiency Disorders. (2005) (1)
Quantitative Differences in the Expression of Specificity Ia.7 (1978) (1)
Mesothelin Is a Novel Disease Marker and Potential Therapeutic Target in Pediatric Acute Myeloid Leukemia (2017) (1)
Cryptic NUP98/NSD1 Translocations Are Highly Prevalent in FLT3/ITD-Positive Acute Myeloid Leukemia and Lead to High Rate of Induction Failure. Report From Children's Oncology Group (2012) (1)
Acute myeloid leukemia with an MN1-ETV6 fusion in a young child with Down syndrome (2022) (1)
Endothelial Cell Niche Promotes Leukemic Transformation of Human Cord Blood Stem/Progenitor Cells Expressing CBFA2T3-GLIS2 Oncogenic Fusion (2021) (0)
Multi-dimensional flow cytometric antigenic comparison of bone marrow from normal, AML and MDS patients (1994) (0)
SNP/CGH Microarray Analysis in MDS: Correlation With Conventional Cytogenetic, FISH and Flow-Cytometric Findings (2017) (0)
Final Results of Phase I/II Trial of Mitoxantrone in Combination with Clofarabine (MITCL) in Children with Relapsed/Refractory Acute Leukemia (2022) (0)
A Distinct Oncofetal B-Cell Transcriptional Program Is Activated in Infant Acute Myeloid Leukemia and Reveals Novel Therapeutic Strategies (2019) (0)
P-050 Flow cytometry combined with SNP/CGH array can definitively identify myelodysplastic syndromes in patients with unexplained cytopenias (2013) (0)
A process for the analysis of hematopoietic cells in a sample. (1988) (0)
Flow Cytometric Assessment of Post Induction Response In Patients with Sub-Optimal Morphologic Response to Induction Chemotherapy- A Report From the Children's Oncology Group AML Protocol AAML0531 (2010) (0)
Flow Cytometric Scoring System as a Diagnostic and Prognostic Tool In Myelodysplastic Syndromes (2010) (0)
Post-Induction-BM Status Combining Minimal Residual Disease, Return to MDS and Hematogones in Predicting Prognosis in Adult AML, (2011) (0)
Evidence of Donor Derived Malignancies Following Hematopoietic Stem Cell Transplantation. (2004) (0)
Myeloid Dyspoiesis as Determined by Flow Cytometry Is a More Powerful Predictor of Post-Transplant Relapse with MDS Than the Marrow Myeloblast Count. (2007) (0)
A BIPHASIC EXTRACTION FOR 2,8-DIOXYADENINE. (1970) (0)
Myeloid Cell Maturation Is Disrupted By Monosomy 7 or By Gain of Additional Genetic Aberrations during Clonal Evolution in Myelodysplastic Syndromes. (2014) (0)
Comprehensive molecular and clinical characterization of NUP98 fusions in pediatric acute myeloid leukemia. (2023) (0)
A clone-specific monoclonal antibody which blocks t cell-mediated cytolysis. Abstr. (1982) (0)
Improving Risk Assessment of AML with a Precision Genomic Strategy to Assess Mutation Clearance (2018) (0)
A Recurrent Immunophenotype at Diagnosis Independently Identifies High Risk Pediatric AML: A Report from the Children's Oncology Group Trial AAML0531 (2015) (0)
CD33 Splicing Polymorphism Is a Strong Predictor of Therapeutic Efficacy of Gemtuzumab Ozogamicin in De Novo AML: Report from COG-AAML0531 Study (2016) (0)
Constancy of buoyant density of escherichia coli and cultured murine cells (1984) (0)
Annals of Clinical Pathology (2014) (0)
High Expression of the Very Late Antigen (VLA)-4 (CD49d) Integrin Predicts for Reduced Risk of Relapse and Better Outcome in Pediatric Acute Myeloid Leukemia (AML): A Report From the Children's Oncology Group. (2009) (0)
outcome after hemopoietic stem cell transplantation scoring in myelodysplastic syndromes correlates with the IPSS and with Myeloid and monocytic dyspoiesis as determined by flow cytometric (2013) (0)
Correcting Flow Cytometric Blast Counts for Blood Contamination in Bone Marrow Aspirates. (2007) (0)
Outcomes Following Allogeneic Stem Cell Transplantation for AML in First Completion Remission Are Comparable between MRD Negative Patients and MRD Positive Patients Receiving Induction Only and Are Superior to MRD Positive Patients Receiving Induction and Additional Therapy (2019) (0)
Engraftment of hematopoietic precursors from patients with myelodysplastic syndrome (MDS) in NOD/SCID mice (2000) (0)
DirectDetermination of the Influenceof the Cell Cycleon the Sijrvival of TumorCellsExposedto CytotoxicAntibodies (1980) (0)
Increased Expression of CD56 on Plasmacytoid Dendritic Cells in Myeloid Leukemia Associated with Down Syndrome (ML-DS) Is Normal Regeneration and Not Measurable Residual Disease (2021) (0)
A method for the analysis of cellular components in a liquid (1989) (0)
Recurrent Genetic Abnormalities Are Reflected in Phenotype at Diagnosis in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group Protocol AAML0531 (2015) (0)
Project Stella: Development and Preclinical Assessment of FOLR1-Directed Chimeric Antigen Receptor T Cells in CBF2AT3-GLIS2/RAM AML (2021) (0)
14 Disruption of precise gene product expression in myelodysplasia (2009) (0)
Lineage-Specific Distribution of CALR EXON 9, JAK2V617F, MPLW515L/K, NPM1 and FLT3 Mutations in Myeloid Disorders (2014) (0)
System to detect abnormal cells using a multidimensional analysis (2006) (0)
137 Standardization of flow cytometry in myelodysplastic syndromes: A report from an international consortium and the European LeukemiaNet Working Group (2011) (0)
The impact of Down syndrome-specific non-malignant hematopoietic regeneration in the bone marrow on the detection of leukemic measurable residual disease. (2023) (0)
T-cell lineage of a Friend virus-induced lymphatic leukemia in athymic rats. (1983) (0)
ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children’s Oncology Group AAML0531 Trial (2019) (0)
CXCR4 (CD184) Expression in Pediatric AML Is Associated with Bone Marrow Retention, Specific Disease Characteristics, and Worse Outcomes: A Report of 1004 Patients from the Children's Oncology Group AAML1031 Protocol (2022) (0)
Clinical Implications of Detection and Clearance of Post-Induction Residual Disease in 2119 Children and Young Adults with AML: Children's Oncology Group Studies AAML0531 and AAML1031 (2017) (0)
Systeme, methode, et article de detection de cellules anormales par analyse pluridimentionnelle (2006) (0)
113 Flow cytometric analysis of erythropoiesis: The last major frontier (2011) (0)
Preclinical studies targeting CD74 with STRO-001 antibody-drug conjugate in acute leukemia. (2023) (0)
Lack of Utility of Chimerism Studies at Day 80 after Myeloablative Hematopoietic Cell Transplantation for Acute Lymphocytic Leukemia. (2006) (0)
Efficacy a nd S afety o f G emtuzumab O zogamicin i n P atients With C D33-Positive A cute M yeloid L eukemia i n F irst Relapse (2001) (0)
Elevated Expression of miR-181a and miR-155 Identify Pediatric AML Patients at High Risk of Induction Failure, A Report from Children's Oncology Group. (2012) (0)
Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues (2022) (0)
Methods for detecting and confirming minimal disease in a cancer patient (2006) (0)
pluripotential stem cell Evidence that juvenile myelomonocytic leukemia can arise from a (2013) (0)
Means for calibrating flow cytometry instruments and other analytical devices. (1987) (0)
Clinical Relevance of Pre- and Post-Transplantation Residual Disease, Hematogones and Natural Killer Cells in Adult Patients with Acute Leukemia (2011) (0)
A process for the analysis of cellular components in a liquid. (1989) (0)
Erratum to “Flow cytometric mean fluorescence intensity: The biophysics behind the number” [Leukemia Res. 32 (2008) 845–846] (2008) (0)
12-1-2016 miR-155 expression and correlation with clinical outcome in pediatric AML : A report from Children ' s Oncology Group . (2019) (0)
Direct Determinationof the Influenceof the Cell Cycle on the Sijrvival of TumorCells Exposedto CytotoxicAntibodies ' (2006) (0)
169 SNP/CGH MICROARRAY ANALYSIS IN MDS: CORRELATION WITH CONVENTIONAL CYTOGENETICS, FISH AND FLOW CYTOMETRIC FINDINGS (2015) (0)
Extending immunophenotyping of acute leukemias: Comparison with normal hematopoietic cells (1993) (0)
Targeting FOLR1 in high-risk CBF2AT3-GLIS2 pediatric AML with STRO-002 FOLR1–antibody-drug conjugate (2022) (0)
NUP98/NSD1 Translocation Further Risk-Stratifies Patients With FLT3/ITD In Acute Myeloid Leukemia: A Report From Children’s Oncology Group and SWOG (2013) (0)
Correlation of Mir-155 Expression with Clinical Outcome in Childhood AML: A Report from Children’s Oncology Group (2014) (0)
Epigenetic Silencing of CD34 in AML and Association with Outcome in KMT2A Fusions (2021) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Michael, R. Loken?

Michael, R. Loken is affiliated with the following schools:

University of Chicago
University of Washington